Evidence map›Paper›PMID 39252322›Full record

ReviewMedicine2024

Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A review.

Hongyang Liu, Min Qiang, Ying Zhang, Hong Wang, Yang Xing, Rui Guo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongyang LiuThe First Hospital of Jilin University, Chang Chun, China.
Min QiangThe First Hospital of Jilin University, Chang Chun, China.
Ying ZhangCancer Center, The First Hospital of Jilin University, Chang Chun, China.
Hong WangCancer Center, The First Hospital of Jilin University, Chang Chun, China.
Yang XingThe First Hospital of Jilin University, Chang Chun, China.
Rui GuoClinical Laboratory, The First Hospital of Jilin University, Chang Chun, China.ORCID 0009-0001-5756-4806

Funding

ilin Science and Technique development grants 20200201472JCilin Science and Technique development grants YDZJ202301ZYTS092
6 · The paper itself

Abstract

KRAS mutations play a critical role in the development and progression of several cancers, including non-small cell lung cancer and pancreatic cancer. Despite advancements in targeted therapies, the management of KRAS-mutant tumors remains challenging. This study leverages bibliometric analysis and a comprehensive review of clinical trials to identify emerging immunotherapies and potential treatments for KRAS-related cancers. Using the Web of Science Core Collection and Citespace, we analyzed publications from January 2008 to March 2023 alongside 52 clinical trials from ClinicalTrials.gov and WHO's registry, concentrating on immune checkpoint blockades (ICBs) and novel therapies. Our study highlights an increased focus on the tumor immune microenvironment and precision therapy. Clinical trials reveal the effectiveness of ICBs and the promising potential of T-cell receptor T-cell therapy and vaccines in treating KRAS-mutant cancers. ICBs, particularly in combination therapies, stand out in managing KRAS-mutant tumors. Identifying the tumor microenvironment and gene co-mutation profiles as key research areas, our findings advocate for multidisciplinary approaches to advance personalized cancer treatment. Future research should integrate genetic, immunological, and computational studies to unveil new therapeutic targets and refine treatment strategies for KRAS-mutant cancers.

Indexed as

BibliometricsImmunotherapyMutationProto-Oncogene Proteins p21(ras)Carcinoma, Non-Small-Cell LungClinical Trials as TopicHumansImmune Checkpoint InhibitorsNeoplasmsTumor MicroenvironmentImmune Checkpoint InhibitorsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID39252322
PMCPMC12431754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.